Skip to content

Homepage

Author: Phathom Pharmaceuticals

Posted Date:

June 23, 2026

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals

June 23, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals

May 29, 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

Phathom Pharmaceuticals

May 29, 2026
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Phathom Pharmaceuticals

May 27, 2026
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals

May 26, 2026
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals

May 25, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals

May 23, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals

February 23, 2026
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Phathom Pharmaceuticals

February 17, 2026
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Phathom Pharmaceuticals

February 7, 2026